Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00839332 · ClinicalTrials.gov registry record · Phase 1
A Study for Participants With Pancreatic Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 157
- Enrollment target
NCT00839332 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 157 participants.
The verdict
NCT00839332, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 157 participants
- Enrollment target
Study Summary
The purpose of the Phase 1 portion of this study was to determine the dose of LY2603618 that can be safely administered 24 hours after gemcitabine treatment. This dose was then used for the Phase 2 portion of the study. The Phase 2 portion of the study evaluated whether LY2603618, when administered 24 hours after gemcitabine therapy, was an effective treatment for participants with pancreatic cancer.
Interventions
- DRUG Gemcitabine
- DRUG LY2603618
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2009-02 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00839332
The ClinicalTrials.gov registry entry for NCT00839332 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00839332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00839332 about?
NCT00839332 is a clinical study titled "A Study for Participants With Pancreatic Cancer". The purpose of the Phase 1 portion of this study was to determine the dose of LY2603618 that can be safely administered 24 hours after gemcitabine treatment. This dose was then used for the Phase 2 portion of the study. The Phase 2 portion of the study evaluated whether LY2603618, when administered ...
What is the current status of trial NCT00839332?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 157 participants. The study started on 2009-02. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00839332?
The interventions under investigation include: Gemcitabine (DRUG), LY2603618 (DRUG).
Who is sponsoring clinical trial NCT00839332?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.